Pembrolizumab for Advanced NSCLC and PS 2-3 | MicrobiomeTrials← Back to trialsNCT05589818
Pembrolizumab for Advanced NSCLC and PS 2-3
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2023-12-05Est. Completion: 2027-05
Enrollment target: 45 participants Locations- Mount Sinai Hospital, New York, New York, United States
Other microbiome trials you might be interested in
Non-small Cell Lung Cancer
This trial is a registrational Phase II/III, randomized, open-label, multicenter study to evaluate the efficacy and safe…
Shanghai, ChinaEst. completion Dec 2032
Recurrent Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Unresectable Lung Non-Small Cell Carcinoma
This phase III trial studies how well an antibody (durvalumab) with chemotherapy and radiation therapy (chemoradiation) …
Anchorage, United StatesEst. completion Dec 31, 2028
Non Small Cell Lung Cancer
The purpose of this study, known as DISCERN, is to compare two different treatments for a type of lung cancer called non…
Birmingham, United StatesEst. completion Apr 27, 2027